Drug intelligence / Profile preview

omega-3 fatty acids (Centre Hospitalier Universitaire de Nice)

Development stage
Discontinued
Lead developer
Centre Hospitalier Universitaire de Nice
Modality
Small Molecules
Administration
Oral
01

Overview

Omega-3 fatty acids are polyunsaturated fatty acids (PUFAs) characterized by a double bond at the third carbon atom from the end of the carbon chain. In the context of the study by Centre Hospitalier Universitaire de Nice, a specific supplementation regimen (1,650 mg/day) was evaluated for its potential to reduce liver volume (hepatomegaly) and fat content (hepatic steatosis) in morbidly obese patients prior to bariatric surgery. The rationale was that omega-3 PUFAs, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), can modulate lipid metabolism, reduce inflammation, and inhibit lipogenesis. However, a multicenter randomized controlled trial (NCT03006016) concluded that a 4-week preoperative course did not significantly reduce liver volume or steatosis compared to placebo.

Other names
n-3 PUFAn3 PUFAn 3 PUFAomega-3 polyunsaturated fatty acidsomega3 polyunsaturated fatty acidsomega 3 polyunsaturated fatty acidsfish oilomega-3-acid ethyl estersomega3-acid ethyl estersomega 3-acid ethyl esters
02

Targets

NR1H3 (Liver X receptor beta)PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)SREBP-1 / SREBF1 (SREBP-1)FFAR4 (Free fatty acid receptor 4)

Beyond the preview

Go deeper on omega-3 fatty acids (Centre Hospitalier Universitaire de Nice).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on omega-3 fatty acids (Centre Hospitalier Universitaire de Nice).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call